Oncolytics Biotech Inc. Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Sep 16, 2025 · CIK: 1129928
Sentiment: neutral
Topics: reporting-status, foreign-private-issuer, sec-filing
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH INC (ONCY) filed a 6-K, confirming foreign private issuer status and 20-F filings.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on September 16, 2025, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is a pharmaceutical preparations company and will file its annual reports under Form 20-F.
Why It Matters
This filing indicates Oncolytics Biotech Inc. is a foreign private issuer and will be filing its annual reports on Form 20-F, which is standard for such companies.
Risk Assessment
Risk Level: low — This is a routine filing confirming the company's reporting status and is not indicative of new risks.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- September 2025 (date) — Reporting period
- 20250916 (date) — Filing date
- Calgary, Alberta, Canada (location) — Company headquarters
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed by Oncolytics Biotech Inc. for the month of September 2025.
What is Oncolytics Biotech Inc.'s principal executive office address?
The company's principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Under which form will Oncolytics Biotech Inc. file its annual reports?
Oncolytics Biotech Inc. will file its annual reports under cover of Form 20-F.
What is the Commission File Number for Oncolytics Biotech Inc.?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512.
Is Oncolytics Biotech Inc. submitting this Form 6-K in paper format?
The filing indicates that the registrant is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1), as that rule only permits paper submission if it's solely to provide an attached annual report to security holders.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-09-16 08:32:50
Filing Documents
- form6kgobletupdate.htm (6-K) — 17KB
- gobletupdate.htm (EX-99.1) — 16KB
- 0001129928-25-000077.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date September 16, 2025 Kirk Look Chief Financial Officer